# Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) as a double-edged sword: leveraging imaging evaluation to maximize benefits and mitigate risks

**Authors:** Mengqi Huang, Chenyu Song, Huasong Cai, Lujie Li, Jiawei Liu, Zhi Dong, Jifei Wang, Yuying Chen, Zhenpeng Peng, Xiaoqi Zhou, Shi-Ting Feng

PMC · DOI: 10.1186/s13244-026-02247-y · Insights into Imaging · 2026-03-17

## TL;DR

This review discusses how medical imaging can help improve outcomes for ALPPS, a complex liver surgery, by guiding patient selection and monitoring.

## Contribution

The paper provides a structured imaging evaluation workflow for ALPPS with evidence-based recommendations.

## Key findings

- Medical imaging is essential for preoperative patient selection in ALPPS.
- Imaging supports interoperative and postoperative monitoring to improve safety and outcomes.
- Evidence-based imaging modalities help reduce ALPPS-related risks.

## Abstract

Surgical resection is the primary treatment option for patients with malignant liver tumors. However, not all patients can be treated by liver resection, primarily due to the critical limitation of insufficient remnant liver volume. The Associating Liver Partition and Portal vein Ligation for Staged Hepatectomy (ALPPS) has been explored as a treatment option for patients with insufficient future liver volume, owing to its ability to induce rapid liver growth. Though ALPPS has opened up opportunities for radical resection, it also presents challenges, including high morbidity and mortality. Therefore, a thorough preoperative evaluation of liver function is essential for patients scheduled for ALPPS. Medical imaging plays a crucial role in providing important information for patient selection and safety monitoring during the ALPPS process. This review outlines the current status of ALPPS, detailing its primary imaging evaluation workflow and the recommended modalities based on available clinical evidence. Where applicable, levels of evidence and strength of recommendations are provided to guide imaging-based decision-making throughout the ALPPS process.

This review provides a comprehensive overview of the ALPPS and elucidates the pivotal role of medical imaging throughout the clinical pathway: (1) preoperative patient selection, (2) staged interoperative assessment, and (3) postoperative surveillance, to ultimately improve patient outcomes.

ALPPS is a promising therapy for malignant liver tumors due to its characteristic of increasing the resectability.Highly selected patients and effective preoperative and interstage management will improve the outcomes and achieve an acceptable morbidity and mortality.Medical imaging offers accurate function and anatomy assessment for ALPPS.

ALPPS is a promising therapy for malignant liver tumors due to its characteristic of increasing the resectability.

Highly selected patients and effective preoperative and interstage management will improve the outcomes and achieve an acceptable morbidity and mortality.

Medical imaging offers accurate function and anatomy assessment for ALPPS.

## Full-text entities

- **Genes:** YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, BLVRB (biliverdin reductase B) [NCBI Gene 645] {aka BVRB, FLR, HEL-S-10, SDR43U1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** dysfunction of the cardiovascular, respiratory, or renal systems (MESH:D015619), Hypertrophy (MESH:D006984), biliary duct stricture (MESH:D003251), biliary complications (MESH:D008107), cirrhotic (MESH:D000094724), CRLM (MESH:D006528), hepatic dysfunction or liver failure (MESH:D017093), portal hypertension (MESH:D006975), pleural effusion (MESH:D010996), cholestasis (MESH:D002779), necrosis (MESH:D009336), Liver cirrhosis (MESH:D008103), hepatic hyperplasia (MESH:D006965), ischemia (MESH:D007511), Colorectal cancer (MESH:D015179), arteriovenous fistula (MESH:D001164), PVE (MESH:C563407), biliary fistulas (MESH:D001658), fistula (MESH:D005402), steatohepatitis (MESH:D005234), inflammation (MESH:D007249), thrombosis (MESH:D013927), bile duct complications (MESH:D001649), esophageal and gastric varices (MESH:D004932), portal vein thrombosis (MESH:D012170), Bile leakage (MESH:D003763), ascites (MESH:D001201), cholangiocarcinoma (MESH:D018281), varicose veins (MESH:D014648), hepatic B or C virus infections (MESH:D006509), infection (MESH:D007239), coagulation disorders (MESH:D001778), bleeding (MESH:D006470), trauma (MESH:D014947), hepatic injury (MESH:D056486), colorectal liver metastases (MESH:D009362), splenomegaly (MESH:D013163), sepsis (MESH:D018805), cholangitis (MESH:D002761), encephalopathy (MESH:D001927), Child-Pugh A (MESH:C562515), liver tumor (MESH:D008113), cyst (MESH:D003560), vascular injuries (MESH:D057772), cancers (MESH:D009369), adhesions (MESH:D000267), hepatic insufficiency (MESH:D048550), hyperbilirubinemia (MESH:D006932), cirrhosis (MESH:D005355)
- **Chemicals:** indocyanine green (MESH:D007208), galactose (MESH:D005690), Gadoxetate (MESH:C073590), 99mTc-mebrofenin (MESH:C034837), 2-[18F]fluoro-2-deoxy-D-galactose (-), glycogen (MESH:D006003)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12996487/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12996487/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12996487/full.md

---
Source: https://tomesphere.com/paper/PMC12996487